Abstract
Objective:
To describe Australian trends in poisoning exposures to attention deficit hyperactivity disorder medication reported to the New South Wales Poisons Information Centre over a 10-year period.
Methods:
This is a large retrospective case series of human exposures to the following medications used for attention deficit hyperactivity disorder: atomoxetine, clonidine, dexamphetamine, guanfacine, lisdexamfetamine and methylphenidate. We extracted exposures from the New South Wales Poisons Information Centre database from 2014 to 2023. Exposures are reported per 100,000 population, data obtained from the Australian Bureau of Statistics. Dispensing data was obtained from the public Pharmaceutical Benefits Scheme Report.
Results:
There were 17,299 exposures reported to New South Wales Poisons Information Centre during this period. Exposure rates increased by 16.5% (95% confidence interval: 15-18%) annually. Groups with some of the greatest annual increases were female adolescents 20.4% (95% confidence interval: 16-25.4%) and children 18.5% (95% confidence interval: 14.7-22.8%). Over half of exposures (9657) were referred into hospital or were in hospital at the time of the call to New South Wales Poisons Information Centre. Sixty percent (10,427) of exposures were unintentional. There was a strong positive correlation between exposures and number of prescriptions, R2 = 0.94, significant F = 4.5 × 10−6.
Conclusion:
Exposures to attention deficit hyperactivity disorder medications present a growing public health issue. Rates have risen annually over the past decade, and the majority require medical attention, placing strain on healthcare resources. There are notable differences in exposure patterns among affected age groups. This highlights the need for targeted preventive measures focused on both quality use of the medication being prescribed as well as considering the circumstances and safety of the individual and household.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
